AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Investing Cash Flow · Q4 FY2024 · quarter ended Dec 2024
Investing cash flow of -€363K in Q4 FY2024
Q4 FY2024 investing cash flow was -€363K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
Currency unavailable · from the cash flow
No Investing Cash Flow data reported for this period type.
Investing Cash Flow vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $248.17M USD | +496.1% | — | 106.8% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $97.94M USD | -191.9% | — | 1323.9% |
| LTM Mar 2026 | $1.69M USD | -97.5% | +56.5% | 20.2% | |
| LTM Mar 2026 | $35K USD | -100.2% | -37.9% | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -98.8% | +9.3% | 106.8% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.